• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Marinus Pharma CS (NQ: MRNS )

    0.3029 -0.0171 (-5.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,819,785
    Open 0.3000
    Bid (Size) 0.3000 (80)
    Ask (Size) 0.3250 (9)
    Prev. Close 0.3200
    Today's Range 0.3029 - 0.3237
    52wk Range 0.2603 - 11.26
    Shares Outstanding 55,084,038
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Tuesday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga

    Performance

    YTD
    -97.09%
    -97.09%
    1 Month
    -82.79%
    -82.79%
    3 Month
    -78.36%
    -78.36%
    6 Month
    -79.39%
    -79.39%
    1 Year
    -95.64%
    -95.64%

    More News

    Read More
    Crude Oil Down 1%; Dow Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Marinus Pharmaceuticals' Oral Seizure Drug Disappoints In Late-Stage Study, Appoints Advisor To Explore Options
    Via Benzinga
    Nasdaq Edges Higher; Honeywell Shares Fall After Q3 Results
    Via Benzinga
    Dow Falls 150 Points; Tesla Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
    From Marinus Pharmaceuticals
    Via Business Wire
    Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
    From Marinus Pharmaceuticals
    Via Business Wire
    Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
    From Marinus Pharmaceuticals
    Via Business Wire
    3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
    Via MarketBeat
    Topics ETFs
    Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
    From Marinus Pharmaceuticals
    Via Business Wire
    Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
    From Marinus Pharmaceuticals
    Via Business Wire
    Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
    Via MarketBeat
    Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
    From Marinus Pharmaceuticals
    Via Business Wire
    Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
    From Marinus Pharmaceuticals
    Via Business Wire
    Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
    From Marinus Pharmaceuticals
    Via Business Wire
    Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
    From Marinus Pharmaceuticals
    Via Business Wire
    MRNS Stock Earnings: Marinus Pharma Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
    From Marinus Pharmaceuticals
    Via Business Wire
    3 Biotech Stocks to Sell in August Before They Crash & Burn
    Via InvestorPlace
    MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Marinus, 2U, Teradata, and Lamb Weston and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Marinus Pharmaceuticals, Inc. (MRNS)
    From The Law Offices of Frank R. Cruz
    Via Business Wire
    MRNS Investors Have Opportunity to Join Marinus Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Marinus
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.